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Guided transport of biologically active molecules to target specific sites in human body has been a focus 
of the research in therapeutics in the past few years. Magnetoliposomes (liposomes entrapping 
magnetic nanoparticles) are of large importance, as they can overcome pharmacokinetics problems of 
the encapsulated drugs and can be guided and localized to the therapeutic sites of interest by external 
magnetic field gradients [1,2]. The use of magneto-sensitive liposomes as nanocarriers allows a safer 
use of powerful anticancer drugs in therapy with lower drug dosage and a more efficient treatment, not 
only in cancer but also in other diseases.  
In this work, manganese ferrite (MnFe2O4) nanoparticles with superparamagnetic behaviour at room 
temperature and size distribution of 26 ± 5 nm, were obtained by coprecipitation method. Structural and 
magnetic properties of the nanoparticles (NPs) were evaluated by XRD, HR-TEM and SQUID. The 
synthesized NPs were either entrapped in liposomes, originating aqueous magnetoliposomes (AMLs), 
or covered with a lipid bilayer, forming solid magnetoliposomes (SMLs), the latter prepared by a new 
method, recently developed for magnetoliposomes based on nickel ferrite NPs [3]. The resulting 
liposomes exhibit sizes below 150 nm (Fig. 1), suitable for biomedical applications. 
Membrane fusion between both types of magnetoliposomes and GUVs (giant unilamellar vesicles), 
used as models of cell membranes, was confirmed by FRET (Förster Resonance Energy Transfer) 
assays [3-5]. For that purpose, the labeled lipid NBD-C12-HPC and the hydrophobic probe Nile Red (or 
the labeled lipid Rhodamine B-DOPE) were both incorporated in the lipid bilayer of magnetoliposomes, 
the NBD moiety acting as the energy donor and the dye Nile Red (or Rhodamine B) as the energy 
acceptor (Fig. 2). After interaction with GUVs, an increase in the NBD (donor) emission band and a 
decrease of acceptor fluorescence is observed (Fig. 2A), confirming membrane fusion (Fig. 2B) [5]. 
A new potential antitumor drug, a thienopyridine derivative (Fig. 3), was successfully incorporated in the 
lipid bilayer of both types of magnetoliposomes. This thienopyridine derivative presents very low growth 
inhibitory concentration values (GI50), between 3.5 and 6.9 µM, when tested in vitro against several 
human tumor cell lines, namely MCF-7 (breast adenocarcinoma), A375-C5 (melanoma) and NCI-H460 
(non-small cell lung cancer) and was the most active of a series of analogues [6]. Moreover, this 
compound has shown a very low affinity for the multidrug resistance protein MDR1 [7], being suitable as 
an anticancer agent. 
These results point to a promising application of magnetoliposomes in oncological therapy, 
simultaneously as hyperthermia agents and as nanocarriers for antitumor drugs, taking also advantage 
of magnetic directioning. 
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Figure 1. TEM image of solid magnetoliposomes (SMLs) containing MnFe2O4 NPs. 
 
 
  
    
Figure 2. A. Fluorescence spectra (exc=400 nm) of AMLs containing both NBD-C12-HPC and Nile Red, 
before and after interaction with GUVs. Inset: Spectral overlap between the fluorescence emission of 
the donor (NBD-C12-HPC) and the absorption of the acceptor (Nile Red). B. Schematic representation of 
membrane fusion between AMLs and GUVs. 
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Figure 3. Structure of the antitumor thienopyridine derivative. 
